The Oncologist Who Wouldn't Give Up on a 'Bad' Breast Cancer Gene — and Changed Treatment Forever

In 1986, an American doctor named Dennis Slamon sat in the crowd at a science conference. He watched a German researcher, Axel Ullrich, present findings on a protein called HER2. Most people in the room didn't see much use for the finding. Slamon did. He talked to Ullrich after the talk. He proposed a team-up between their labs.

That partnership took more than a decade. It faced pushback from the drug company that was supposed to fund it. In the end, it produced one of the most important cancer drugs of modern times: trastuzumab, sold under the brand name Herceptin.

Slamon led the hematology-oncology unit at UCLA. He and Ullrich found that a change in the HER2 gene showed up in about a quarter to a third of aggressive breast cancers. Before this discovery, these tumors tended to grow fast and resist treatment. Slamon had an idea. He thought scientists could build an antibody that blocked the HER2 protein. That antibody could target cancer cells directly. It would spare healthy tissue in a way normal chemotherapy could not.

The idea sounds obvious now. At the time, it was hard to get anyone to fund it. Slamon has said he faced real doubt at Genentech, the biotech company he needed for backing. He finally won support for a small early study. The results were strong enough to unlock full drug development. About twelve years after that first conference conversation, Herceptin was approved. It became a targeted therapy just for HER2-positive breast cancer.

What's medically accurate about this story

The science behind Slamon's work has held up well. It has also grown a lot since then. HER2 stands for human epidermal growth factor receptor 2. It's a protein. When a gene copies too much of it, cancer cells grow and divide faster. Before targeted therapy existed, a HER2-positive diagnosis usually meant a worse outlook than HER2-negative breast cancer at the same stage.

Herceptin works by attaching to the HER2 protein on cancer cells. This blocks the growth signals the protein would send. It also flags those cells so the immune system can attack them. Herceptin was one of the first successful "targeted therapies." Unlike regular chemotherapy, which kills cells broadly, a targeted therapy is built around one specific feature of a tumor. This drug helped create a new approach to treatment: test the tumor first, then match a drug to what you find. Doctors now use this approach across many types of cancer.

Today, HER2 testing is a standard step in diagnosing and staging breast cancer. Doctors test a sample of the tumor in a lab. HER2-positive breast cancer used to mean a harder outlook. Now doctors treat it with a wide and growing set of HER2-targeted drugs. Herceptin was the first.

What gets oversimplified in the retelling

The story of "one scientist's persistence changed everything" is mostly true. But it leaves out a lot of teamwork. Ullrich found HER2 first. Clinical trials needed staff and patients willing to join. Many labs spent decades improving HER2-targeted treatment beyond the original drug. Slamon's role was real and important. But "lone genius" stories can hide how much cancer research relies on teamwork and small steady steps. They can also hide how much depends on patients who join early trials with unknown outcomes.

Herceptin changed a lot, but it is not a cure-all. It only works well for HER2-positive disease, which is just part of all breast cancers. Like any cancer treatment, it has side effects. Doctors use it as one part of a larger treatment plan, not on its own.

Signs and symptoms

You can't tell if a breast cancer is HER2-positive just by looking. Doctors find that out only through lab testing of tumor tissue after a diagnosis. Still, some general warning signs should prompt a checkup. These include a new lump or mass, a change in breast size or shape, dimpled skin, changes or discharge from the nipple, and pain that won't go away. Most of these signs have harmless causes. But you should still get them checked.

Prevention and screening angle

You can't prevent HER2-positive status. It comes from changes in the tumor's own genes, not from lifestyle. This makes early detection even more important. Regular screening, like mammograms, is still the best way to catch any breast cancer early. Catching it early gives you the widest range of treatment choices. If you have a strong family history of breast or ovarian cancer, talk to a doctor. Ask whether you need earlier or extra screening, or genetic counseling.

Stories like Slamon's show how cancer research funding turns into real treatments. Those treatments change survival odds for entire groups of patients. Groups like the National Cancer Information Foundation work to keep this science clear and free for everyone to read.

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has checked it unless one is listed above.

Cancer Explained is published by the National Cancer Information Foundation. This is not medical advice. It does not recommend any test or treatment.

See an error, old source, or unclear wording? Tell us.